given
period
outbreak
fatal
human
infect
caus
coronavirus
develop
optim
coronaviru
vaccin
platform
capabl
rapid
product
ongo
prioriti
chapter
describ
use
insect
cell
express
system
rapid
product
recombin
vaccin
sever
acut
respiratori
syndrom
coronaviru
sar
detail
method
present
express
purifi
cation
releas
test
sar
recombin
spike
protein
antigen
follow
adjuv
formul
anim
test
method
herein
describ
rapid
develop
highli
protect
sar
vaccin
equal
suit
rapid
develop
vaccin
fatal
human
coronaviru
infect
eg
mer
coronaviru
sever
acut
respiratori
syndrom
coronaviru
sar
fi
rst
identifi
ed
seri
fatal
pneumonia
case
character
infl
ammatori
cell
infi
ltrate
diffus
alveolar
damag
start
hong
kong
spread
countri
control
quarantin
measur
human
infect
fatal
high
elderli
overal
case
fatal
rate
recent
middl
east
respiratori
syndrom
coronaviru
mer
caus
seri
seriou
case
fatal
human
infect
given
risk
futur
seriou
human
coronaviru
outbreak
develop
suitabl
vaccin
platform
protect
virus
major
prioriti
vaccin
present
sever
challeng
includ
rapid
outbreak
develop
henc
need
rapid
vaccin
manufactur
henc
success
coronaviru
vaccin
platform
must
overcom
multipl
challeng
sar
cov
positivestrand
rna
viru
kb
length
open
read
frame
initi
sar
vaccin
candid
produc
inactiv
viru
inactiv
wholeviru
vaccin
provid
modest
protect
induc
lowneutr
antibodi
titer
protect
infect
associ
faster
lung
clearanc
viru
howev
immun
mice
inactiv
vaccin
either
alon
formul
alum
adjuv
result
sever
lung
eosinophil
patholog
respons
viru
challeng
similar
enhanc
lung
patholog
seen
sar
viru
reexposur
primari
infect
henc
major
challeng
develop
sar
vaccin
identifi
strategi
avoid
lung
eosinophil
patholog
challeng
develop
vaccin
base
inactiv
sar
viru
need
highcontain
biosafeti
level
cgmp
manufactur
facil
make
vaccin
manufactur
complex
expens
restrict
number
vaccin
dose
rapidli
manufactur
counter
challeng
would
prefer
produc
subunit
vaccin
like
inactiv
viru
abl
induc
neutral
antibodi
sarscov
rather
requir
manufactur
abl
produc
regular
recombin
protein
manufactur
environ
potenti
solut
problem
lie
coronaviru
spike
protein
protein
case
sar
viru
bind
angiotensinconvert
enzym
induc
receptormedi
viru
endocytosi
therebi
critic
viru
entri
target
cell
protein
could
therebi
provid
ideal
antigen
induc
neutral
antibodi
sar
viru
howev
immun
protein
anim
model
provid
protect
sar
viru
proteinimmun
anim
subsequ
challeng
live
viru
develop
sever
lung
eosinophil
immunopatholog
problem
exacerb
even
protein
vaccin
formul
alum
adjuv
similar
problem
lung
eosinophil
immunopatholog
seen
virus
includ
respiratori
syncyti
viru
rsv
vaccin
prime
excess
harm
lung
immun
respons
upon
subsequ
viru
exposur
lung
eosinophil
immunopatholog
exacerb
formul
vaccin
adjuv
induc
excess
immun
polar
eg
aluminum
salt
adjuv
henc
protein
would
appear
ideal
sar
vaccin
antigen
fi
rst
need
reduc
risk
lung
eosinophil
immunopatholog
induc
vaccin
describ
method
use
develop
manufactur
recombin
subunit
vaccin
base
protein
antigen
lack
transmembran
cytoplasm
domain
express
use
baculoviru
insect
cell
express
platform
protein
antigen
low
immunogen
step
also
describ
formul
safe
effect
adjuv
aluminum
adjuv
contraind
sar
vaccin
given
may
exacerb
lung
eosinophil
patholog
instead
method
describ
formul
protein
safe
effect
adjuv
base
delta
inulin
previous
shown
anim
model
enhanc
immunogen
broad
rang
viral
bacteri
antigen
also
shown
safe
effect
preliminari
human
clinic
trial
notabl
advax
adjuv
recent
shown
enhanc
immunogen
protect
confer
inactiv
recombin
sar
vaccin
without
excess
bia
alum
adjuv
henc
without
risk
induc
lung
eosinophil
immunopatholog
project
recombin
baculoviru
design
express
ectodomain
sar
protein
lack
transmembran
cytoplasm
domain
recombin
protein
express
vector
term
sar
truncat
version
protein
select
contain
receptorbind
domain
rbd
abl
express
insect
cell
higher
level
fulllength
membranebound
version
sar
rbd
shown
induc
neutral
antibodi
sar
cov
infect
expr
sf
insect
cell
recombin
baculoviru
protein
express
secret
cell
cultur
medium
procedur
detail
purifi
sar
protein
follow
product
protein
baculovirusinsect
cell
system
process
design
l
ferment
l
bioreactor
may
adjust
scale
necessari
follow
harvest
sar
protein
purifi
ed
column
chromatographi
schemat
provid
fig
fi
rst
step
supernat
fl
owe
link
unospher
uno
deae
sepharos
column
dna
protein
impur
remov
sar
protein
remain
fl
ow
fl
ow
uno
deae
step
appli
lentil
lectin
sepharos
sar
bind
impur
remov
follow
elut
lentil
lectin
sepharos
column
protein
concentr
buffer
exchang
ultrafi
ltration
retent
ultrafi
ltration
step
process
fi
lter
purifi
ed
protein
store
prior
intend
use
purifi
ed
sar
protein
mix
condit
suspens
delta
inulin
adjuv
particl
either
asept
fi
lled
singledos
vial
load
directli
syring
readi
vaccin
lastli
adjuv
sar
vaccin
test
efficaci
safeti
anim
immunogen
sar
challeng
model
begin
collect
fl
ow
link
column
l
carboy
uv
trace
begin
rise
wash
link
column
mm
tri
ph
collect
wash
carboy
column
fl
ow
collect
l
wash
stop
collect
wash
uv
trace
return
baselin
proceed
lentil
lectin
captur
chromatographi
pack
column
ml
lentil
lectin
sepharos
see
note
attach
process
tank
accord
manufactur
instruct
fill
process
tank
water
inject
wfi
close
permeat
valv
circul
wfi
system
mlmin
min
open
permeat
valv
increas
circul
rate
mlmin
continu
total
volum
diafi
ltration
buffer
equal
time
volum
initi
concentr
retent
use
volum
process
tank
approxim
equal
initi
concentr
retent
volum
diafi
ltration
retent
process
diafi
ltration
retent
fi
lter
steril
nalgen
polycarbon
bottl
bulk
drug
substanc
remov
aliquot
test
store
bulk
drug
substanc
test
accept
criteria
sar
list
tabl
preservativefre
steril
suspens
delta
inulin
microparticl
mgml
bicarbon
buffer
combin
vaccin
antigen
enhanc
immun
balanc
fashion
enhanc
reduc
immun
bia
cpg
oligonucleotid
per
mg
delta
inulin
ad
adjuv
simpl
admixtur
adjuv
formul
administ
mice
standard
dose
mg
delta
inulin
per
mous
irrespect
antigen
dose
adjuv
formul
bulk
drug
substanc
laminar
fl
ow
hood
asept
simpl
admixtur
suspens
bulk
drug
substanc
draw
combin
milki
white
suspens
ml
insulin
syring
immedi
prior
immun
vaccin
immunogen
studi
conveni
perform
adult
femal
balbc
mice
week
age
also
perform
strain
see
note
mice
immun
twice
week
apart
intramuscular
inject
thigh
order
mimic
common
rout
human
vaccin
administr
maximum
volum
inject
adult
mous
thigh
muscl
vaccin
reduc
volum
provid
vaccin
reactogen
larger
vaccin
volum
administ
inject
amount
multipl
leg
start
week
postimmun
interv
week
mice
bled
use
cheek
vein
bleed
use
lancet
order
obtain
blood
serum
cell
prolifer
assay
splenocyt
label
cfse
invitrogen
life
technolog
min
rt
cfse
start
react
expos
aqueou
solut
therefor
import
avoid
dilut
cfse
immedi
cell
label
vitro
antivir
assay
serum
reduc
fb
gentamicin
ad
medium
fi
nal
concentr
balbc
mice
infect
urbani
strain
three
fi
day
infect
lung
remov
homogen
use
reinfect
subsequ
group
mice
infect
step
continu
time
balbc
mice
lung
viru
plaquepurifi
ed
three
time
yield
viru
caus
sever
lung
diseas
mortal
infect
mice
viru
verifi
ed
sarscov
enzymelink
immunosorb
assay
elisa
polymeras
chain
reaction
pcr
experi
involv
infecti
sarscov
virus
need
conduct
approv
biosafeti
level
laboratori
day
postviru
challeng
fi
mice
immun
control
group
sacrifi
ced
lung
harvest
gross
patholog
lung
score
lung
weight
lung
viru
titer
measur
antisar
igg
lung
homogen
lung
score
sampl
mous
lung
lobe
weigh
place
petri
dish
lung
score
base
surfac
appear
lung
lung
assign
score
rang
indic
lung
look
normal
denot
entir
surfac
area
lung
infl
ame
exhibit
plumcolor
lung
discolor
assess
effect
vaccin
lung
eosinophil
immunopatholog
immun
vehicletr
mice
sacrifi
ced
day
postviru
challeng
lung
remov
formalinfi
xed
lung
mount
paraffi
n
block
paraffi
nembed
lung
section
stain
hematoxylin
eosin
h
e
rat
monoclon
antibodi
clone
eosinophil
major
basic
protein
mbp
lee
laboratori
mayo
clinic
arizona
follow
standard
ihc
procedur
dab
chromogen
identifi
es
eosinophil
brownstain
cell
eosinophil
infi
ltration
score
without
know
anim
ident
use
h
estain
slide
overal
infi
ltration
score
assign
section
accord
amount
eosinophil
parenchyma
distribut
lung
score
eosinophil
score
mild
eosinophil
infi
ltration
score
moder
infi
ltration
score
sever
infi
ltration
confi
rmation
immunohistochemistri
eosinophil
major
basic
protein
perform
section
highest
score
treatment
group
remaind
mice
follow
week
postchalleng
assess
surviv
surviv
analysi
done
use
kaplanmei
method
logrank
test
analysi
reveal
statist
signifi
cant
differ
among
treatment
group
pairwis
comparison
survivor
curv
analyz
mantelcox
logrank
test
rel
signifi
canc
adjust
bonferronicorrect
signifi
canc
threshold
number
treatment
comparison
done
group
comparison
viru
titer
done
use
analysi
varianc
determin
experiment
signifi
canc
follow
newmankeul
pairwis
comparison
test
protein
cultur
supernat
rich
cultur
medium
practic
precaut
taken
prevent
microbi
growth
contain
steril
buffer
fi
ltere
column
chromatographi
system
thoroughli
sanit
use
process
intermedi
process
immedi
store
column
pack
ahead
time
store
accord
resin
manufactur
recommend
column
may
equilibr
harvest
cultur
cultur
supernat
contain
may
load
onto
link
uno
sdeae
column
immedi
harvest
lentil
lectin
sepharos
column
may
load
immedi
complet
uno
sdeae
step
load
may
run
overnight
balbc
mice
typic
use
vaccin
studi
immun
bia
henc
good
make
antibodi
respons
wherea
mice
bia
